Company NanoViricides, Inc.

Equities

NNVC

US6300873022

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Nyse Other stock markets 04:10:00 2024-04-26 pm EDT			5-day change	1st Jan Change
1.1 ^USD	-0.90%		0.00%	+7.84%

Feb. 14	NanoViricides, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	CI
Feb. 01	NanoViricides, Inc. Announces Clinical Trial Demonstration of Safety and Tolerability of NV-CoV-2 Has Implications Beyond COVID Treatment, Explains NanoViricides - NV-387 Could be As Revolutionary as Antibiotics	CI

NanoViricides, Inc. is a development stage company, which is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. Its lead drug candidate is NV-CoV-2 (API NV-387) for the treatment of COVID-19 disease caused by SARS-CoV-2 coronavirus. Its other advanced candidate is NV-HHV-1 for the treatment of Shingles. NV-CoV-2 is its nanoviricide drug candidate for COVID-19 containing the nanoviricide API, NV-387. NV-CoV-2-R is its other drug candidate for COVID-19, which is made up of NV-387 with remdesivir encapsulated within its polymeric micelles. It has developed both of its own drug candidates, NV-CoV-2 and NV-CoV-2-R independently. It is also developing drugs against a number of viral diseases, including RSV, oral and genital Herpes, viral diseases of the eye, including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu and others.

Number of employees: 7

Managers	Title	Age	Since
Anil Diwan CEO	Chief Executive Officer	66	05-03-31
Meeta Vyas DFI	Director of Finance/CFO	66	13-05-12
Jayant Tatake CTO	Chief Tech/Sci/R&D Officer	-	10-03-02
Randall Barton CTO	Chief Tech/Sci/R&D Officer	-	10-03-02

Members of the board	Title	Age	Since
Brian Zucker BRD	Director/Board Member	62	20-11-12
Anil Diwan CEO	Chief Executive Officer	66	05-03-31
Makarand Jawadekar BRD	Director/Board Member	73	20-02-06
Theodore Rokita BRD	Director/Board Member	54	20-05-14

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	11,779,000	11,235,047 ( 95.38 %)	0	88.68 %
Stock B	0	890,511	0	0

Name	Equities	%	Valuation
Theracour Pharma, Inc. 3.998 %	470,959	3.998 %	546 312 $
Vanguard Global Advisers LLC 3.892 %	458,416	3.892 %	531 763 $
BlackRock Institutional Trust Co. NA 1.352 %	159,297	1.352 %	184 785 $
Compagnie Lombard Odier SCmA 1.273 %	150,000	1.273 %	174 000 $
Geode Capital Management LLC 0.9295 %	109,489	0.9295 %	127 007 $
Renaissance Technologies LLC 0.6664 %	78,500	0.6664 %	91 060 $
Bridgeway Capital Management LLC 0.5012 %	59,039	0.5012 %	68 485 $
STATE STREET CORPORATION 0.3558 %	41,906	0.3558 %	48 611 $
City National Bank (Los Angeles, California) 0.2592 %	30,535	0.2592 %	35 421 $
Northern Trust Investments, Inc.(Investment Management) 0.2518 %	29,664	0.2518 %	34 410 $

Name	Equities	%	Valuation
Theracour Pharma, Inc. 137.70 %	681,859	137.70 %	790 956 $
Anil Diwan 23.56 %	116,683	23.56 %	135 352 $
Meeta Vyas 3.279 %	16,237	3.279 %	18 835 $

NanoViricides, Inc.

1 Controls Drive

06484, Shelton

+203 937 6137

http://www.nanoviricides.com

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.1 USD

Average target price

6.5 USD

Spread / Average Target

+490.91%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
NANOVIRICIDES, INC.	+7.84%	12.96M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs